Oncogematologiya

Aims & Scope

The main purpose of the Oncohematology journal is to publish up-to-date information on clinical, experimental and fundamental scientific research, diagnostics and treatment options, as well as other materials on all relevant issues in oncohematology.

The journal’s objectives are to inform various specialists who provide advisory and therapeutic assistance to patients with oncohematological diseases about current advances, including the latest methods for the diagnosis and treatment of malignant blood diseases.

The journal is an interdisciplinary scientific publication uniting doctors of various specialties ‒ hematologists, oncologists, surgeons, radiation therapists, intensive care specialist, pathologists, etc. ‒ to form an interdisciplinary therapy approach in order to improve the treatment efficacy of patients with hematological malignancies.

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)
• Embase

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Copyright url
• Plagiarism url
• Preservation url
• Apc url
• License

Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Medicine, ensuring accessibility and quality in research dissemination.

This journal does not charge a mandatory Article Processing Charge (APC). However, optional open access publication may incur fees based on the publisher’s policies.

Explore journals without APCs for alternative publishing options.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• STANDARDIZATION OF FLOW CYTOMETRIC MINIMAL RESIDUAL DISEASE MONITORING IN CHILDREN WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA. RUSSIA–BELARUS MULTICENTER GROUP EXPERIENCE

  Citation: 26

  Authors: A. M., M. V., E. V., T. Yu., L. V., M. S., А. B., V. P., А. A., G. А., S. A., S. A., L. G., O. V., A. I.

• RUSSIAN-BELARUSIAN MULTICENTER GROUP STANDARD GUIDELINES FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA FLOW CYTOMETRIC DIAGNOSTICS

  Citation: 26

  Authors: I. A., T. Yu., L. V., G. A., М. V., A. M.

• ANEMIA OF CHRONIC DISEASE: FEATURES OF PATHOGENESIS AND POSSIBLE THERAPEUTIC CORRECTION (LITERATURE REVIEW AND RESULTS OF OWN RESEARCH)

  Citation: 17

  Authors: V. Т., Е. R., E. V., S. P., O. A.

• Pediatric acute lymphoblastic leukemia treatment protocols improvement: emphasis on minimal residual disease

  Citation: 16

  Authors: M. A., T. T.

• Anemia of chronic diseases: the important aspects of pathogenesis and treatment

  Citation: 15

  Authors: O. A.

• EPIDEMIOLOGY OF MULTIPLE MYELOMA ACCORDING TO THE КIROV REGION POPULATION REGISTERS

  Citation: 14

  Authors: A. S., S. V., N. V., N. M., I. V.

• Adoptitive immunotherapy with genetically engineered T lymphocytes modified to express chimeric antigen receptors

  Citation: 14

  Authors: A. А., M. А., V. B.

• MUCORMYCOSIS IN ONCOHEMATOLOGY PATIENTS (results of the prospective study)

  Citation: 12

  Authors: N. N., S. N., O. V., T. S., Y. L., A. G., M. O., I. A., A. S., E. G., N. V., E. I., A. V., M. B., I. S., O. S., V. N., N. I., G. K., L. S., B. V.

• New proteasome inhibitors in the management of multiple myeloma

  Citation: 12

  Authors: S. V.

• Integrated laboratory coagulation tests in hypercoagulation diagnosis and thrombosis risk assessment. Part I. The pathophysiology of thrombosis and hypercoagulation

  Citation: 9

  Authors: E. N., F. I., M. A.